Pfizer Korea to focus on arthritis drugs as moneymaker

Published: 2003-04-22 07:00:00

Updated: 2003-04-22 07:00:00

With Pfizer and Pharmacia combining operations on April 16, Pfizer Korea seems like to concentrate its sales on Bextra, Celebrex and Xalatan as new cash cow in the current downturn in the domestic pharmaceutical industry.

"We will use the depth and experience of the Pfizer sales force to incre...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK